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Abstract. Recent studies have suggested that retinol binding 
protein 4 (RBP4), an adipocytokine related to insulin 
resistance (IR), may play an important role in the develop-
ment of atherosclerosis and cardiovascular diseases (CVD). 
Abnormal proliferation and migration of vascular smooth 
muscle cells (VSMCs) is one of the most common causes 
of atherosclerosis. Hyperinsulinism promotes proliferation 
of VSMCs through the MAPK pathway. However, whether 
RBP4 is involved in insulin-induced proliferation of VSMCs 
leading to atherosclerosis remains unclear. In the present 
study, we evaluated the role of RBP4 and the potential 
relevance of signaling pathways in this process. Different 
concentrations of RBP4 (1 and 4 µg/ml) were added to rat 
aortic smooth muscle cells (RASMCs) during insulin-induced 
proliferation. The levels of cell growth signaling pathway 
proteins ERK1/2, p-ERK1/2, JAK2, p-JAK2, STAT3 and 
p-STAT3 were assessed by western blotting in order to iden-
tify the pathway(s) that are activated during insulin-induced 
proliferation. The specific inhibitors of ERK1/2 (PD98059) 
and JAK2 (AG490) were used to confirm our findings. Insulin 
induced proliferation of RASMCs in a concentration- and 
time-dependent manner, and increased the expression of 
ERK1/2, p-ERK1/2, JAK2, p-JAK2, STAT3 and p-STAT3 in 
a time-dependent manner. RBP4 enhanced insulin-induced 
proliferation of RASMCs and expression of p-ERK1/2 and 
p-JAK2. RBP4-induced proliferation of RASMCs was 
reduced by the ERK1/2 inhibitor, while it was unaffected by 
the JAK2 inhibitor. These results suggest that RBP4 medi-
ates VSMC proliferation induced by insulin via activation of 
the MAPK pathway, and highlight RBP4 as a modulator of 
atherosclerosis in hyperinsulinemia, therby enhancing our 
understanding on a number of unexpected aspects of CVD.
Introduction
The endocrine function of adipose tissue has been elucidated 
in recent years, with the identification of adipocytokines such 
as leptin, adiponectin and resistin. Adipose tissue produces 
numerous cytokines and hormones, which act as autocrine, 
paracrine and endocrine factors and participate in the patho-
physiological process of insulin resistance (IR) and chronic 
inflammation (1,2). Retinol binding protein 4 (RBP4) is an 
adipocytokine related to IR (3). This was first shown in mice 
by Yang et al (3), who observed that knockout mice for the gene 
encoding adipose-specific glucose transporter-4 (GLUT-4) 
were insulin resistant in muscle and liver, and displayed 
increased expression of the RBP4 gene. Graham et al (4) 
subsequently measured the serum RBP4 level, insulin resis-
tance, and components of the metabolic syndrome in lean and 
obese individuals with or without type 2 diabetes, and found 
that the serum level of RBP4 correlates with insulin resistance. 
Additional studies further proved that the level of RBP4 in the 
blood associates with IR (5-8). IR is followed by compensatory 
hyperinsulinemia. It is widely accepted that hyperinsulinemia 
and insulin resistance are the main risk factors of cardiovas-
cular diseases (CVD), eventually leading to the formation and 
development of atherosclerosis (9).
Vascular smooth muscle cells (VSMCs) have been exten-
sively used to study the pathological mechanisms underlying 
atherosclerosis. Proliferation and migration of VSMCs is of 
important value for the formation of coronary atherosclerosis 
and the development of coronary heart disease (CHD). Insulin 
is a highly potent cell growth factor, which can promote 
VSMC proliferation and DNA synthesis, and plays an impor-
tant role in the formation of atherosclerosis (10,11). Recently, 
RBP4, an adipocytokine related to IR, has been suggested to 
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play an important role in the occurrence and development of 
atherosclerosis and CVD (12-14). However, whether RBP4 is 
involved in insulin-induced proliferation of VSMCs leading to 
atherosclerosis remains unclear.
Proliferation and migration of VSMCs are related 
to a variety of signal transduction pathways, such as the 
mitogen-activated protein kinase (MAPK) and the JAK/
STAT pathway. Insulin activates the MAPK pathway through 
the Grb2/SOS and RAS proteins to promote cell growth and 
proliferation, and collagen synthesis (15-17). IR is followed 
by compensatory hyperinsulinemia, which promotes insulin-
induced proliferation of VSMCs via the SHC/Raf/MAPK 
pathway, and accelerates artery atherosclerosis (18). JAK/STAT 
is another important signal transduction pathway mediating 
cell proliferation. Binding of cytokines such as interferon, 
5-hydroxytryptamine, platelet-derived growth factor and 
others to the specific receptor activates the protein tyrosine 
kinase (PTK) Janus kinase (JAK), thereby activating signal 
transducer and activator of transcription (STAT), and inducing 
cell proliferation. Previous studies (19-21) have shown that 
the JAK/STAT signaling pathway plays an important role in 
VSMC proliferation.
Insulin promotes proliferation of VSMCs to induce 
formation of atherosclerosis through the MAPK pathway. 
Ost et al (22) examined the mechanisms of action of RBP4 
in primary human adipocytes. RBP4-treated adipocytes 
displayed the same molecular defects in insulin signaling, 
mediated by the insulin receptor substrate (IRS) protein 1 
and the MAP kinase, as adipocytes from patients with type 2 
diabetes. Takebayashi et al (23) further showed that RBP4 has 
a robust acute effect on the enhancement of NO production 
via stimulating part of the PI3K/Akt/eNOS pathway and inhib-
iting insulin-induced ET-1 secretion, probably via the MAPK 
pathway, eventually causing vasodilatation. However, whether 
RBP4 is involved in insulin-induced proliferation of VSMCs 
leading to atherosclerosis remains unclear. In the present 
study, we evaluated the role of RBP4 in this process and the 
underlying signaling pathways.
Materials and methods
Reagents. RBP4 protein was purchased from Sino Βiological 
Inc. (Beijing, China) and was dissolved in a solution 
comprising sterile 50 mM Tris, 10 mM CaCl2 and 150 mM 
NaCl at pH 7.5, at a final concentration of 500 µg/ml. Mouse 
anti-extracellular signal-regulated kinase (ERK)1/2 and 
-phospho-ERK1/2 (p-ERK1/2) monoclonal antibodies, and 
rabbit polyclonal anti-JAK2, -p-JAK2, -signal transducer and 
activator of transcription (STAT) 3 and -p-STAT3 antibodies 
were purchased from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA, USA). HRP-conjugated goat anti-rabbit and anti-
rat IgGs were purchased from ZSGB-Bio (Beijing, China). 
The specific inhibitors of ERK1/2 PD098059, and of JAK2 
AG490, were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Supersignal West Pico Chemiluminescent substrate was 
purchased from Thermo Scientific (Rockford, IL, USA).
Cell culture. The rat aortic smooth muscle cell (RASMC) line 
A10 was obtained from the American Type Culture Collection 
(Manassas, VA, USA). The cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM) containing 10% fetal 
bovine serum (FBS), penicillin (100 U/ml), streptomycin 
(100 µg/ml) and NaHCO3 (3.7 g/l), in a humidified atmosphere 
of 5% CO2 at 37˚C. Cells from passages 7 and 15 were used 
for the experiments.
Cell proliferation assays. Cell proliferation was analyzed by 
using the MTT and a cell cycle assay. For the MTT assay, 
RASMCs were seeded in 96-well plates at a density of 
0.6-1.0x10
4 cells/well in DMEM supplemented with 10% FBS. 
After 24 h, the medium was replaced with DMEM containing 
1% FBS to render the cells quiescent for 24 h. Then, cells were 
incubated for different time periods in DMEM containing 
1% FBS and different concentrations of insulin. DMEM 
containing 1% FBS and RBP4 (1 or 4 µg/ml), PD098059 
(5x10
-5 M), or AG490 (5x10
-5 M) was added to the cells, 
followed by treatment with insulin (10
-5 M). Finally, 20 µl of 
5 mg/ml MTT solution was added to each well and incubated 
for 4 h. The supernatants were aspirated, and the formazan 
crystals in each well were dissolved in 150 µl dimethyl 
sulfoxide. Cell proliferation was assessed by measuring the 
absorbance at 490 nm using a microplate reader (DTX800; 
Beckman Coulter, Brea, CA, USA).
For cell cycle analysis by flow cytometry, RASMCs were 
seeded in 6-well culture plates (1x10
5 cells/well). After 24 h, 
the medium was replaced with DMEM containing 1% FBS 
to render the cells quiescent for 24 h. Then, RASMCs were 
pre-treated with RBP4 (1 or 4 µg/ml) for 1 h, or PD098059 
(5x10
-5 M)/AG490 (5x10
-5 M) for 10 min, followed by treat-
ment with insulin (10
-5 M) for 24 h. After 24 h, cells were 
trypsinized and washed with phosphate-buffered saline (PBS) 
twice before fixing in ice-cold 70% ethanol at 4˚C overnight. 
After removing ethanol by centrifugation, cells were washed 
with PBS and treated, for 20 min in the dark, with 50 µg/ml 
propidium iodide solution (Sigma-Aldrich) combined with 
100 µg/ml DNase-free RNase, 0.1% Triton X-100 and 
0.1 mM EDTA in PBS. After washing with PBS, propidium 
iodide-stained cells were subjected to cell cycle analysis using 
a FACScan flow cytometer (Becton Dickinson, Mountain 
View, CA, USA) and the FlowJo 7.1.0 software (Tree Star Inc., 
Ashland, OR, USA). At least 10,000 cells were counted for 
each sample. Data are presented as the percentage of cells in 
a given subpopulation.
Western blotting. RASMCs were lysed in RIPA lysis buffer 
containing 0.1 M phenylmethylsulfonyl fluoride. After centrif-
ugation at 12,000 rpm for 20 min, the protein concentrations 
of the supernatants were determined with the bicinchoninic 
acid assay (Sigma-Aldrich). Equal amounts of protein were 
mixed with sodium dodecyl sulfate (SDS) buffer and incu-
bated at 100˚C for 5 min before loading. Then, equal amounts 
of total protein were loaded and separated on a 15% SDS poly-
acrylamide gel by electrophoresis at a constant 90-V voltage 
for 2.5 h. Proteins were transferred under a standard module 
onto a polyvinylidene difluoride membrane (EMD Millipore, 
Billerica, MA, USA) for 45 min. The membrane was blocked 
with a 5% dry milk/Tris-buffered saline-Tween-20 (TBST) 
solution for 1 h at room temperature, and then probed with 
primary antibodies (anti-ERK1/2, -p-ERK1/2, -JAK2, 
-p-JAK2, -STAT3, -p-STAT3, dilution 1:1,000; -β-actin, MOLECULAR MEDICINE REPORTS  9:  1634-1640,  2014 1636
1:3,000) in a 5% dry milk/TBST solution overnight at 4˚C. 
The membrane was rinsed several times with TBST buffer and 
then incubated with HRP-conjugated secondary antibodies 
(1:5,000) for 1 h at room temperature. Excess secondary 
antibody was removed by 3-4 washes in TBST buffer and 
the targeted protein bands were detected using an enhanced 
chemiluminescence (ECL) detection kit, followed by exposure 
of the membrane to an X-ray film. Protein bands were scanned 
and quantified using Image J software version 1.40 (National 
Institutes of Health, Bethesda, MD, USA). The quantified data 
for each protein were normalized to those for β-actin.
Statistical analysis. Data are expressed as means ± SD and were 
statistically analyzed by Student's paired t-test for pairwise 
comparisons or ANOVA followed by Newman-Student-Keuls 
test for comparisons among multiple groups. P<0.05 was 
considered to indicate a statistically significant difference. The 
SPSS 13.0 software was used for the analyses (IBM, Armonk, 
NY, USA).
Results
Proliferation of RAVSMCs induced by insulin. As previously 
mentioned, hyperinsulinemia is considered an independent 
risk factor for atherosclerosis and CVD. Insulin can promote 
VSMC proliferation and DNA synthesis, playing an important 
role in the formation of atherosclerosis. We therefore used 
insulin to stimulate proliferation in vitro. In line with results 
from a previous study (24), insulin induced proliferation of 
RASMCs in a concentration- and time-dependent manner, as 
shown by the increase in formazan absorbance (Fig. 1) and in 
the proportion of cells detected at the S and G2 phases (data 
not shown).
Expression of ERK1/2, p-ERK1/2, JAK2, p-JAK2, STAT3, 
p-STAT3 in RASMCs is induced by insulin. Since insulin 
induced proliferation of RASMCs in a concentration- and 
time-dependent manner, we used the most effective concentra-
tion (10
-5 M) of insulin to further study the activation of signal 
transduction pathways related to cell proliferation. Insulin 
treatment enhanced the protein levels of ERK1/2, p-ERK1/2, 
JAK2, p-JAK2, STAT3, and p-STAT3 in a time-dependent 
manner, as shown by western blotting analysis (Fig. 2).
RBP4 enhances insulin-induced proliferation of RASMCs. 
RBP4 enhanced the insulin-induced proliferation of RASMCs, 
as shown by the increase in formazan absorbance and in the 
proportion of cells at the S + G2 phases (Fig. 3A and B). The 
phosphorylation of ERK1/2, JAK2 and STAT3 is an indicator 
of the activation of the MAPK and the JAK/STAT signal 
transduction pathways. Notably, the expression of p-ERK and 
p-JAK2 that was induced by insulin was further enhanced 
by RBP4 treatment, while that of p-STAT3 remained 
unchanged (Fig. 3C).
Involvement of ERK1/2 and JAK2/STAT3 pathways in the 
enhancement of RASMC proliferation by RBP4. To determine 
whether the ERK1/2 and/or the JAK2/STAT3 pathway are 
involved in the enhancement of insulin-induced cell prolifera-
tion caused by RBP4, PD98059 (the specific ERK1/2 inhibitor) 
and AG490 (the specific JAK2 inhibitor) were used. As shown 
by the MTT assay and flow cytometry, pre-treatment of cells 
with PD98059 (5x10
-5 M) significantly (P<0.01) inhibited 
proliferation of RASMCs, while pre-treatment with AG490 
(5x10
-5 M) had no effect on proliferation (Fig. 4).
Discussion
The present study examined the effect of RBP4 on 
insulin-induced proliferation of RASMCs. The main findings 
are the following: ⅰ) insulin induced proliferation of RASMCs 
via the MAPK and JAK2/STAT3 pathways; ⅱ) RBP4 enhanced 
insulin-induced proliferation of RASMCs and ⅲ) RBP4 
enhanced insulin-induced proliferation of RASMCs via the 
MAPK, but not the JAK2/STAT3 pathway. Collectively, these 
findings indicate that RBP4 may play an important role in 
the mediation of signals related to proliferation of VSMCs 
induced by insulin, which suggests that RBP4 may contribute 
to vascular remodeling in hyperinsulinemia.
Since the first study of Yang et al (3) on RBP4 effects in 
mice, related studies on RBP4 and insulin resistance, obesity, 
type 2 diabetes, and CHD have provided contradictory results. 
Mahmoudi et al (11) did not find a significant difference in 
the RBP4 level between a non-diabetic population with CHD 
and healthy controls. Mallat et al (12) attempted to prove that 
RBP4 can be used as a predictor of CHD. The authors studied 
1,036 patients with CHD in a period of six years, and found 
that the risk of CHD increased in cases of increased RBP4 
level. However, following adjustment of the data for other 
CHD risk factors, the positive correlation between the RBP4 
level and the risk of heart disease proved not to be statistically 
Figure 1. Proliferation of rat aortic smooth muscle cells (RASMCs) induced 
by insulin is (A) concentration-dependent and (B) time-dependent, with a 
peak observed at 24 h. Proliferation was determined using the MTT assay. 
Data come from 8-10 independent experiments. 
**P<0.01 vs. control (0 h/0 M).
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significant, thereby suggesting that RBP4 may not be a robust 
predictor of CHD. However, there are studies that showed 
that RBP4 positively and significantly correlates to carotid 
intima-media thickness, which is an atherosclerosis indicator, 
and negatively correlates to flow-mediated dilatation (25,26). 
Independent correlations between RBP4 and the low-density 
lipoprotein or the oxidized low-density lipoprotein have also 
been reported (27,28). In addition, Cabré et al (29) showed that 
the RBP4 level is significantly higher in atherosclerotic patients 
with primary type 2 diabetes mellitus than in those without 
atherosclerosis. Overall, a potential correlation between 
RBP4 and atherosclerosis and CHD can not be unequivocally 
claimed. Atherosclerosis is the basic pathogenetic cause of 
CHD, while abnormal proliferation and migration of VSMCs 
is one of the most common causes of atherosclerosis, vascular 
restenosis and other CVDs.
Binding of insulin to insulin receptors (InsR) in the target 
organs and tissues activates the MAPK pathway through the 
Grb2/SOS and RAS proteins, thereby regulating gene tran-
scription to promote cell growth and proliferation. In IR, even 
when pancreatic β cells show a good function, compensa-
tory hyperinsulinemia occurs and promotes insulin-induced 
proliferation of VSMCs via the SHC/Raf/MAPK pathway; 
in these conditions, hyperinsulinemia accelerates arterial 
atherosclerosis.
In agreement with a previous study (24), we showed that 
insulin induces proliferation of RASMCs in a concentra-
tion-dependent manner, with a 10-5 M concentration exerting 
the strongest effect. We further showed that insulin induces 
expression of ERK1/2 and p-ERK1/2 in a time-dependent 
manner, and that this effect is the strongest at 24 h of treat-
ment. The present and previous studies overall confirm that 
treatment with high concentrations of insulin stimulates 
RASMC proliferation through activation of MAPKs. 
Notably, we also observed a time-dependent stimulation of 
the expression of JAK, p-JAK, STAT3 and p-STAT3 by high 
concentrations of insulin in RASMCs. This result strongly 
suggests that the JAK/STAT cell proliferation signal trans-
duction pathway is also regulated by high concentrations of 
insulin. Therefore, JAK/STAT pathways not only mediate 
Figure 2. Expression of ERK2, p-ERK2, JAK2, p-JAK2, STAT3, p-STAT3 in rat aortic smooth muscle cells (RASMCs) induced by insulin. (A) Insulin induces 
the expression of ERK1/2, p-ERK1/2 in a time-dependent manner, with the maximum level of both proteins detected at 24 h. (B) Insulin induces the expression 
of JAK2, p-JAK2 in a time-dependent manner, with the maximum level of JAK2 detected at 12 h, and of p-JAK2 at 24 h. (C) Insulin induces the expression of 
STAT3, p-STAT3 in a time-dependent manner, with the maximum level of STAT3 detected at 12 h, and of p-STAT3 at 24 h. Blots are representative of three 
independent experiments. 
*P<0.05, 
**P<0.01 vs. control (0' without insulin).
  A   B
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Figure 3. Retinol binding protein 4 (RBP4) increases insulin-induced proliferation of rat aortic smooth muscle cells (RASMCs), as determined by (A) the 
MTT assay and (B) flow cytometry. (C) RBP4 increases the protein level of p-ERK and p-JAK, but not that of p-STAT3. The blot is representative of three 
independent experiments. **P<0.01 vs. Con; #P<0.05, ##P<0.01 vs. Ins. Con, untreated cells; Ins, cells treated with 10-5 M insulin for 24 h; +RBP4(L), cells 
pre-treated with RBP4 (1 µg/ml) for 1 h prior to treatment with insulin; +RBP4(H), cells pre-treated with RBP4 (4 µg/ml) for 1 h prior to treatment with insulin. 
Data come from 8-10 independent experiments.
Figure 4. Involvement of the ERK1/2 and JAK2/STAT3 pathways in retinol binding protein 4 (RBP4)-mediated enhancement of rat aortic smooth muscle 
cell (RASMC) proliferation. (A) Proliferation of RASMCs measured by the MTT assay. RBP4-induced proliferation of RASMCs is inhibited in the presence 
of the JAK1/2 inhibitor PD98059 (5x10-5 M) but not of the JAK2 inhibitor AG490 (5x10-5 M). Data come from 3-8 independent experiments. *P<0.05, **P<0.01 
vs. Con; ##P<0.01 vs. Ins (10-5 M) + RBP4 (4 µg/ml). (B) Cell cycle analysis by flow cytometry. Control, untreated cells; Ins + RBP4, cells treated with 10-5 M 
Ins + RBP4 (4 µg/ml) for 24 h; +PD98059, cells pre-treated with PD98059 (5x10-5 M) for 10 min prior to treatment with insulin and RBP4; +AG490, cells pre-
treated with AG490 (5x10
-5 M) for 10 min prior to treatment with insulin and RBP4; DMSO, wild-type cells treated with 0.1% DMSO (PD98059 isovolumetric).
  A   B
  C
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proliferation of VSMCs induced by IL-6 (19), platelet-derived 
growth factor BB (30) and IL-18 (31), but may also have a role 
in hyperinsulinism-induced atherosclerosis.
In the present study, RASMCs were pre-incubated with 
RBP4 (1 or 4 µg/ml) for 1 h prior to treatment with 10
-5 M 
insulin, and these experiments demonstrated that RBP4 
significantly increases the ability of insulin to induce smooth 
muscle cell proliferation. The percentage of RBP4-treated 
cells that were detected at the S and G2 phases was consider-
ably higher than that of the control cells. This study also found 
that RBP4 significantly enhances the insulin-induced level of 
p-ERK and p-JAK proteins, from which we can infer that the 
activation (phosphorylation) of ERK and JAK is significantly 
enhanced. No significant effect on STAT3 phosphorylation 
was observed under these conditions, thus we conclude that 
RBP4 enhances insulin-induced smooth muscle cell prolif-
eration via the MAPK pathway. Pre-treatment of RASMCs 
with the ERK1/2 inhibitor PD98059 effectively inhibited 
the observed effects of RBP4, including cell cycle changes. 
However, treatment with the JAK inhibitor AG490 had no 
significant effect on RBP4-induced cell proliferation, and 
cell cycle distribution did not change. These findings argue 
for the involvement of the MAPK pathway in the promotion 
of the insulin-induced proliferation of RASMCs by RBP4.
Binding of insulin to the insulin receptor (InsR) mediates, 
via a number of signal transduction pathways, a variety of 
physiological effects in the target organs and tissues. There 
are at least two insulin-related signal transduction pathways: 
one is the phosphatidylinositide 3 kinase (PI-3K) pathway, 
which is activated by IRS; the second is the MAPK pathway, 
which is activated via the Grb2/SOS and RAS proteins. A 
high level of plasma RBP4 can enhance insulin resistance 
through inhibition of IRS-1 and activation of phosphatidylino-
sitol 3-kinase (PI3-K) in skeletal muscles (3). In agreement 
with a study (22) reporting that RBP4 reduces insulin-induced 
phosphorylation of IRS-1 and ERK1/2 in human adipose 
tissue, Takebayashi et al (23) found that RBP4 increases the 
production of NO by stimulating part of the PI3K/Akt/eNOS 
pathway in vascular endothelial cells, and leads to vasodila-
tion through inhibition of phosphorylation of ERK1/2 and 
insulin-induced secretion of endothelin. However, in the 
present study, RBP4 was shown to enhance phosphorylation 
of ERK1/2 in RASMCs, thereby promoting the proliferation 
of smooth muscle cells, and this effect was attenuated by 
the specific inhibitor of ERK1/2 PD98059. In target tissues 
and organs of individuals with obesity and type 2 diabetes, 
the IRS/PI-3K pathway is impaired, but the Shc/Raf/MAPK 
pathway remains intact, and is even stimulated (18). This 
‘selective insulin resistance’ phenomenon mitigates insulin 
metabolic regulation, including its antagonistic effect 
in atherosclerosis. RBP4 can inhibit phosphorylation of 
IRS-1 (3,22), then promote selective insulin resistance to 
enhance insulin-induced proliferation of vascular smooth 
muscle cells, and synthesis of collagen and growth factors.
In conclusion, the present study showed that insulin induces 
proliferation of RASMCs in a concentration- and time-depen-
dent manner via the MAPK and JAK2/STAT3 pathways. In 
addition, we report, for the first time to the best of our knowl-
edge, that RBP4 enhances RASMC proliferation induced by 
insulin via activation of the MAPK signaling pathway. Since 
this is a novel finding, additional research is needed to confirm it 
and further investigate the underlying mechanisms. The results 
from the present and previous studies indicate that RBP4 has 
a prominent role as a modulator of atherosclerosis in hyperin-
sulinemia, and may contribute to a better understanding of the 
numerous unexpected aspects of CVDs.
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